Outlook Therapeutics Inc
OTLK1.250USD
+0.040+3.31%
收盘 11/05, 16:00（美东）报价延迟15分钟
54.35M总市值
亏损市盈率 TTM
关于 Outlook Therapeutics Inc 公司
Outlook Therapeutics, Inc. 是一家生物制药公司。该公司专注于开发和商业化 ONS-5010/LYTENAVA (bevacizumab-gamma)，这是一种用于治疗视网膜疾病的贝伐单抗眼科制剂。该公司正在推进 ONS-5010/LYTENAVA (bevacizumab-vikg)，这是一种用于治疗湿性老年性黄斑变性 (wet AMD)、糖尿病性黄斑水肿 (DME) 和视网膜分支静脉阻塞 (BRVO) 的贝伐单抗研究性眼科制剂。 Bevacizumab-vikg 是一种重组人源化单克隆抗体 (mAb)，可选择性地与人类血管内皮生长因子 (VEGF) 的所有同工型高亲和力结合，并通过空间阻断 VEGF 与内皮细胞表面受体 Flt-1 (VEGFR-1) 和 KDR (VEGFR-2) 的结合来中和 VEGF 的生物活性。ONS-5010/LYTENAVA 由三项临床试验组成，分别称为 NORSE ONE、NORSE TWO 和 NORSE THREE。
Outlook Therapeutics Inc简介
公司代码OTLK
公司名称Outlook Therapeutics Inc
上市日期Jun 13, 2016
CEOMr. Robert Charles Jahr
员工数量23
证券类型Ordinary Share
年结日Jun 13
公司地址111 S. Wood Avenue
城市ISELIN
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编08830
电话16096193990
网址https://outlooktherapeutics.com/
公司代码OTLK
上市日期Jun 13, 2016
CEOMr. Robert Charles Jahr
Outlook Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Mr. Julian S. Gangolli
Mr. Julian S. Gangolli
Independent Director
Independent Director
--
--
Prof. Dr. Gerd Auffarth, M.D.
Prof. Dr. Gerd Auffarth, M.D.
Independent Director
Independent Director
--
--
Mr. Andong Huang
Mr. Andong Huang
Independent Director
Independent Director
--
--
Mr. Ralph H. (Randy) Thurman
Mr. Ralph H. (Randy) Thurman
Lead Independent Director
Lead Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月2日 周日
更新时间: 11月2日 周日
持股股东
股东类型
持股股东
持股股东
占比
GMS Ventures and Investments
30.51%
Syntone Ventures LLC
3.84%
Schonfeld Strategic Advisors LLC
3.07%
The Vanguard Group, Inc.
2.82%
Morgan Stanley & Co. LLC
0.95%
其他
58.81%
持股股东
持股股东
占比
GMS Ventures and Investments
30.51%
Syntone Ventures LLC
3.84%
Schonfeld Strategic Advisors LLC
3.07%
The Vanguard Group, Inc.
2.82%
Morgan Stanley & Co. LLC
0.95%
其他
58.81%
股东类型
持股股东
占比
Corporation
34.35%
Investment Advisor
5.83%
Hedge Fund
4.26%
Investment Advisor/Hedge Fund
1.65%
Research Firm
1.54%
Venture Capital
0.19%
Individual Investor
0.17%
Bank and Trust
0.12%
Family Office
0.02%
其他
51.87%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
192
6.03M
13.58%
-8.59M
2025Q2
200
23.11M
54.78%
+2.16M
2025Q1
206
18.99M
51.79%
+1.54M
2024Q4
199
13.00M
49.47%
-2.41M
2024Q3
196
16.85M
70.81%
+1.73M
2024Q2
189
16.98M
71.93%
+3.50M
2024Q1
185
15.51M
74.39%
+7.93M
2023Q4
178
7.21M
55.91%
-348.31K
2023Q3
180
7.28M
56.56%
-251.17K
2023Q2
176
8.12M
63.26%
-296.08K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GMS Ventures and Investments
13.55M
30.51%
+4.29M
+46.25%
May 27, 2025
Syntone Ventures LLC
1.71M
3.84%
+714.29K
+72.07%
Apr 17, 2024
Schonfeld Strategic Advisors LLC
1.36M
3.07%
-187.94K
-12.10%
Jun 30, 2025
The Vanguard Group, Inc.
1.25M
2.82%
+414.19K
+49.46%
Jun 30, 2025
Morgan Stanley & Co. LLC
421.83K
0.95%
+390.24K
+1235.32%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
366.20K
0.82%
--
--
Jun 30, 2025
Millennium Management LLC
338.57K
0.76%
+338.57K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
330.26K
0.74%
-846.69K
-71.94%
Jun 30, 2025
Geode Capital Management, L.L.C.
265.63K
0.6%
-168.22K
-38.77%
Jun 30, 2025
Fidelity Management & Research Company LLC
170.50K
0.38%
-4.74K
-2.70%
Jun 30, 2025
查看更多
持股ETF
更新时间: 42 分钟前
更新时间: 42 分钟前
机构名称
占比
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 3000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Global X Russell 2000 ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Russell 3000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
公告日期
类型
比率
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
